End-to-end support to advance gene therapies for rare retinal diseases

As a promising therapeutic candidate targeting rare inherited retinal diseases was spun out of an academic medical center, an emerging biotech needed a knowledgeable and agile partner to provide analytical testing of their product and ensure the project followed an expedited timeline. Learn how Labcorp served as an integral partner in many functional areas as the biologic progressed to the clinic -- and how Labcorp later supported clinical operations for several trials in the program.